🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

HealthEquity founder sells $34,000 in stock, buys $5,600 worth

Published 06/06/2024, 11:58 AM
HQY
-

HealthEquity, Inc. (NASDAQ:HQY) founder and Vice Chairman Stephen Neeleman has recently engaged in stock transactions involving the company's shares, according to the latest SEC filings. On June 4, 2024, Neeleman sold 400 shares of HealthEquity common stock at a price of $85.0 per share, totaling $34,000. On the same day, he also acquired 400 shares at $14.0 each, amounting to $5,600.

These transactions were executed under a prearranged Rule 10b5-1 trading plan, which Neeleman adopted on December 8, 2023. Such plans allow company insiders to set up a trading schedule in advance to avoid any accusations of trading on insider information.

The sale and purchase of shares have resulted in a slight change in Neeleman's holdings in HealthEquity. Following these transactions, it was reported that he owns 90,515 shares directly. Additionally, the SEC filing disclosed indirect ownership through the Stephen and Christine Neeleman Trust and Neeleman Family Holdings, LLC, with shares totaling 559,235 and 203,000, respectively.

The filing also included information on derivative securities, specifically stock options, which are rights to buy shares at a predetermined price. Neeleman holds stock options exercisable immediately, with expiration dates ranging from 2024 to 2029 and conversion prices between $14.00 and $73.61.

Investors often monitor insider transactions as they can provide insights into the executives' perspectives on the company's current valuation and future prospects. HealthEquity's stock performance and Neeleman's recent transactions will likely continue to be of interest to current and potential shareholders.

In other recent news, HealthEquity, Inc. reported significant growth in the first quarter of fiscal year 2025, with an 18% increase in revenue, a 36% increase in adjusted EBITDA, and a 22% increase in HSA assets. This growth has prompted several analyst firms to revise their price targets for the company. JPMorgan raised its target to $115, citing HealthEquity's consistent market share growth within the HSA sector and the potential of its Enhanced Rates product. KeyBanc increased its target to $100, based on improved custodial yields. BofA Securities raised its target to $105, highlighting HealthEquity's strong quarterly performance and margin expansion. Baird also increased its target to $104, applauding the company's robust financial performance and upbeat forecast. These recent developments underscore the positive outlook on HealthEquity's business trajectory and its strategic positioning within the growing HSA market.

InvestingPro Insights

As HealthEquity, Inc. (NASDAQ:HQY) navigates through the market, recent data from InvestingPro provides a closer look at the company's financial health and performance. The company currently holds a market capitalization of $7.38 billion, which is a testament to its substantial presence in the industry. With a trailing twelve-month revenue of $1.04 billion, HealthEquity has demonstrated a solid revenue growth of 15.8% as of Q1 2023. This growth is further underscored by a quarterly revenue increase of 17.66% for Q1 2023, indicating a strong start to the year.

InvestingPro Tips suggest that HealthEquity's net income is expected to grow this year, a potential indicator of robust financial health and a positive outlook for the future. Additionally, the company has been the subject of optimistic revisions, with 7 analysts revising their earnings estimates upwards for the upcoming period. This could signal confidence in the company's ability to exceed expectations and deliver favorable results.

Despite trading at a high earnings multiple, with a P/E ratio of 90.71, the company's stock has historically shown low price volatility. This may appeal to investors looking for stability in their investments. HealthEquity also operates with a moderate level of debt and has liquid assets that exceed its short-term obligations, providing further assurance of the company's financial resilience.

For those interested in delving deeper into HealthEquity's financials and stock performance, InvestingPro offers a wealth of additional tips—12 to be exact. These can be accessed by visiting the dedicated page for HealthEquity at https://www.investing.com/pro/HQY. Remember, using the coupon code PRONEWS24 will grant an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering valuable insights for informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.